Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Drops By 69.1%

SciSparc Ltd. (NASDAQ:SPRC) was the recipient of a significant decrease in short interest in the month of December. As of December 15th, there was short interest totaling 57,651 shares, a decrease of 69.1% from the November 30th total of 186,467 shares. Based on an average daily volume of 1,586,485 shares, the days-to-cover ratio is currently 0.0 days. Approximately 10.9% of the company’s shares are sold short. Approximately 10.9% of the company’s shares are sold short. Based on an average daily volume of 1,586,485 shares, the days-to-cover ratio is currently 0.0 days.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on SPRC. Wall Street Zen raised shares of SciSparc to a “sell” rating in a research note on Saturday, September 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of SciSparc in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

SciSparc Price Performance

SciSparc stock opened at $1.39 on Thursday. The company’s 50 day simple moving average is $2.56 and its 200-day simple moving average is $4.31. SciSparc has a 1 year low of $1.35 and a 1 year high of $37.59.

SciSparc (NASDAQ:SPRC) last posted its earnings results on Tuesday, November 18th. The company reported ($3.08) earnings per share for the quarter. The company had revenue of $0.23 million for the quarter.

About SciSparc

SciSparc AG is a clinical?stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low?intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.